FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

In 2024, a warning by the U.S. Food and Drug Administration (FDA) focused on the potential dangers of compounded semaglutide and tirzepatide, with the agency citing reports of unanticipated health ...

The US Food and Drug Administration (FDA) has stood by an earlier decision confirming that the tirzepatide shortage is over. The end of the shortage means that pharmacies making compounded ...